From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

The FDA's top vaccine official is stepping down after just 3 months in a role that upset drug companies, patient groups and some political leaders.

Biogen touts “New Ventures” team; Why drug prices will remain high; San Diego biotech companies struggle to secure funding.